MBIO — Mustang Bio Share Price
0.000.00%
Last trade - 00:00- $11.21m
- $9.88m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | -322.45% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on translating medical breakthroughs in cell and gene therapies into potential cures for cancers and rare genetic diseases. The Company has partnered with medical institutions to advance the development of chimeric antigen receptor modified T cell (CAR-T) therapies across multiple cancers, as well as lentiviral gene therapies for severe combined immunodeficiency. Its pipeline is focused in three core areas: CAR T therapies for hematologic malignancies, CAR T therapies for solid tumors and gene therapies for rare genetic disorders. It is developing a CAR T therapy for hematologic malignancies in partnership with Fred Hutch targeting CD20 (MB-106). In partnership with St. Jude, its X-linked Severe Combined Immunodeficiency (XSCID) gene therapy programs (MB-117 and MB-217) are being developed under an exclusive license to develop a potentially curative treatment for XSCID, a rare genetic immune system condition.
Directors
- Michael Weiss CHM (55)
- Manuel Litchman PRE (67)
- Brian Achenbach SVF (56)
- Lindsay Rosenwald DRC (66)
- Adam Chill IND (53)
- Neil Herskowitz IND (64)
- Michael Zelefsky IND (60)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- March 13th, 2015
- Public Since
- August 22nd, 2017
- No. of Shareholders
- 71
- No. of Employees
- 80
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 31,263,217
- Address
- 377 PLANTATION STREET, WORCESTER, 01605
- Web
- https://www.mustangbio.com/
- Phone
- +1 7816524500
- Auditors
- KPMG LLP
Upcoming Events for MBIO
Q2 2024 Mustang Bio Inc Earnings Release
Q3 2024 Mustang Bio Inc Earnings Release
Similar to MBIO
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
What is the Mustang Bio share price?
As of Today at 22:11 UTC, shares in Mustang Bio are trading at $0.56. This share price information is delayed by 15 minutes.
How has the Mustang Bio share price performed this year?
Shares in Mustang Bio last closed at $0.56 and the price had moved by -91.95% over the past 365 days. In terms of relative price strength the Mustang Bio share price has underperformed the S&P500 Index by -93.6% over the past year.
What are the analyst and broker recommendations for Mustang Bio?
The overall consensus recommendation for Mustang Bio is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Mustang Bio dividend yield?
Mustang Bio does not currently pay a dividend.
Does Mustang Bio pay a dividend?
Mustang Bio does not currently pay a dividend.
When does Mustang Bio next pay dividends?
Mustang Bio does not currently pay a dividend.
How do I buy Mustang Bio shares?
To buy shares in Mustang Bio you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Mustang Bio?
As of the previous close price of $0.56, shares in Mustang Bio had a market capitalisation of $6.95m.
Where are Mustang Bio shares listed?
Here are the trading details for Mustang Bio:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: MBIO
What kind of share is Mustang Bio?
Based on an overall assessment of its quality, value and momentum Mustang Bio is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Mustang Bio share price forecast for 2024?
The analyst consensus target price for shares in Mustang Bio is $10.00. That is 1700.83% above the last closing price of $0.56.
Analysts covering Mustang Bio currently have a consensus Earnings Per Share (EPS) forecast of -$3.57 for the next financial year.
What is the trend in the Mustang Bio share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Mustang Bio. Over the past six months, its share price has underperformed the S&P500 Index by -59.9%.
As of the last closing price of $0.56, shares in Mustang Bio were trading -54.32% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Mustang Bio PE Ratio?
The Mustang Bio PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.56.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Mustang Bio?
Mustang Bio's management team is headed by:
- Michael Weiss - CHM
- Manuel Litchman - PRE
- Brian Achenbach - SVF
- Lindsay Rosenwald - DRC
- Adam Chill - IND
- Neil Herskowitz - IND
- Michael Zelefsky - IND